A multi-nozzle nebuliser does not improve tissue drug delivery during PIPAC
Background Multi-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue drug delivery. Nonetheless, the advantages of such devices over one-nozzle nebulisers have not been demonstrated thus far. In this...
Saved in:
Published in | Surgical endoscopy Vol. 38; no. 10; pp. 5832 - 5841 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
01.10.2024
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
Multi-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue drug delivery. Nonetheless, the advantages of such devices over one-nozzle nebulisers have not been demonstrated thus far. In this study, we compared the performance of multi- and one-nozzle nebulisers by conducting physical and ex vivo pharmacological experiments.
Methods
The one-nozzle nebuliser Capnopen® and the multi-nozzle nebuliser were the subjects of this study. In physical experiments, the aerosol droplet size was measured by laser diffraction spectroscopy. Spatial spray patterns were depicted on blotting paper. Pharmacological experiments were performed on the enhanced inverted bovine urinary bladder model, demonstrating real-time tissue drug delivery, aerosol sedimentation and homogeneity of doxorubicin and cisplatin tissue distribution.
Results
The multi-nozzle nebuliser had a sixfold greater aerosolisation flow and a threefold greater angle of aerosolisation than Capnopen®. The aerosol particle size and distribution range were higher than that of Capnopen®. Spray patterns on blotting paper were more extensive with the multi-nozzle nebuliser. Real-time tissue drug delivery with the multi-nozzle nebuliser was over 100 ml within 1 min, and the aerosol sedimentation was 48.9% ± 21.2%, which was not significantly different from that of Capnopen®. The doxorubicin and cisplatin tissue concentrations were greater with Capnopen®. Although there was no significant difference in the homogeneity of doxorubicin distribution between the two devices, the homogeneity of cisplatin distribution was significantly higher with Capnopen®.
Conclusion
The multi-nozzle PIPAC nebuliser did not fulfil expectations. Even though the surface spray patterns were broader with the multi-nozzle nebuliser, the tissue drug homogeneity and concentration were greater with Capnopen®.
Graphical Abstract |
---|---|
AbstractList | Multi-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue drug delivery. Nonetheless, the advantages of such devices over one-nozzle nebulisers have not been demonstrated thus far. In this study, we compared the performance of multi- and one-nozzle nebulisers by conducting physical and ex vivo pharmacological experiments.
The one-nozzle nebuliser Capnopen® and the multi-nozzle nebuliser were the subjects of this study. In physical experiments, the aerosol droplet size was measured by laser diffraction spectroscopy. Spatial spray patterns were depicted on blotting paper. Pharmacological experiments were performed on the enhanced inverted bovine urinary bladder model, demonstrating real-time tissue drug delivery, aerosol sedimentation and homogeneity of doxorubicin and cisplatin tissue distribution.
The multi-nozzle nebuliser had a sixfold greater aerosolisation flow and a threefold greater angle of aerosolisation than Capnopen®. The aerosol particle size and distribution range were higher than that of Capnopen®. Spray patterns on blotting paper were more extensive with the multi-nozzle nebuliser. Real-time tissue drug delivery with the multi-nozzle nebuliser was over 100 ml within 1 min, and the aerosol sedimentation was 48.9% ± 21.2%, which was not significantly different from that of Capnopen®. The doxorubicin and cisplatin tissue concentrations were greater with Capnopen®. Although there was no significant difference in the homogeneity of doxorubicin distribution between the two devices, the homogeneity of cisplatin distribution was significantly higher with Capnopen®.
The multi-nozzle PIPAC nebuliser did not fulfil expectations. Even though the surface spray patterns were broader with the multi-nozzle nebuliser, the tissue drug homogeneity and concentration were greater with Capnopen®. Multi-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue drug delivery. Nonetheless, the advantages of such devices over one-nozzle nebulisers have not been demonstrated thus far. In this study, we compared the performance of multi- and one-nozzle nebulisers by conducting physical and ex vivo pharmacological experiments.BACKGROUNDMulti-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue drug delivery. Nonetheless, the advantages of such devices over one-nozzle nebulisers have not been demonstrated thus far. In this study, we compared the performance of multi- and one-nozzle nebulisers by conducting physical and ex vivo pharmacological experiments.The one-nozzle nebuliser Capnopen® and the multi-nozzle nebuliser were the subjects of this study. In physical experiments, the aerosol droplet size was measured by laser diffraction spectroscopy. Spatial spray patterns were depicted on blotting paper. Pharmacological experiments were performed on the enhanced inverted bovine urinary bladder model, demonstrating real-time tissue drug delivery, aerosol sedimentation and homogeneity of doxorubicin and cisplatin tissue distribution.METHODSThe one-nozzle nebuliser Capnopen® and the multi-nozzle nebuliser were the subjects of this study. In physical experiments, the aerosol droplet size was measured by laser diffraction spectroscopy. Spatial spray patterns were depicted on blotting paper. Pharmacological experiments were performed on the enhanced inverted bovine urinary bladder model, demonstrating real-time tissue drug delivery, aerosol sedimentation and homogeneity of doxorubicin and cisplatin tissue distribution.The multi-nozzle nebuliser had a sixfold greater aerosolisation flow and a threefold greater angle of aerosolisation than Capnopen®. The aerosol particle size and distribution range were higher than that of Capnopen®. Spray patterns on blotting paper were more extensive with the multi-nozzle nebuliser. Real-time tissue drug delivery with the multi-nozzle nebuliser was over 100 ml within 1 min, and the aerosol sedimentation was 48.9% ± 21.2%, which was not significantly different from that of Capnopen®. The doxorubicin and cisplatin tissue concentrations were greater with Capnopen®. Although there was no significant difference in the homogeneity of doxorubicin distribution between the two devices, the homogeneity of cisplatin distribution was significantly higher with Capnopen®.RESULTSThe multi-nozzle nebuliser had a sixfold greater aerosolisation flow and a threefold greater angle of aerosolisation than Capnopen®. The aerosol particle size and distribution range were higher than that of Capnopen®. Spray patterns on blotting paper were more extensive with the multi-nozzle nebuliser. Real-time tissue drug delivery with the multi-nozzle nebuliser was over 100 ml within 1 min, and the aerosol sedimentation was 48.9% ± 21.2%, which was not significantly different from that of Capnopen®. The doxorubicin and cisplatin tissue concentrations were greater with Capnopen®. Although there was no significant difference in the homogeneity of doxorubicin distribution between the two devices, the homogeneity of cisplatin distribution was significantly higher with Capnopen®.The multi-nozzle PIPAC nebuliser did not fulfil expectations. Even though the surface spray patterns were broader with the multi-nozzle nebuliser, the tissue drug homogeneity and concentration were greater with Capnopen®.CONCLUSIONThe multi-nozzle PIPAC nebuliser did not fulfil expectations. Even though the surface spray patterns were broader with the multi-nozzle nebuliser, the tissue drug homogeneity and concentration were greater with Capnopen®. Background Multi-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue drug delivery. Nonetheless, the advantages of such devices over one-nozzle nebulisers have not been demonstrated thus far. In this study, we compared the performance of multi- and one-nozzle nebulisers by conducting physical and ex vivo pharmacological experiments. Methods The one-nozzle nebuliser Capnopen® and the multi-nozzle nebuliser were the subjects of this study. In physical experiments, the aerosol droplet size was measured by laser diffraction spectroscopy. Spatial spray patterns were depicted on blotting paper. Pharmacological experiments were performed on the enhanced inverted bovine urinary bladder model, demonstrating real-time tissue drug delivery, aerosol sedimentation and homogeneity of doxorubicin and cisplatin tissue distribution. Results The multi-nozzle nebuliser had a sixfold greater aerosolisation flow and a threefold greater angle of aerosolisation than Capnopen®. The aerosol particle size and distribution range were higher than that of Capnopen®. Spray patterns on blotting paper were more extensive with the multi-nozzle nebuliser. Real-time tissue drug delivery with the multi-nozzle nebuliser was over 100 ml within 1 min, and the aerosol sedimentation was 48.9% ± 21.2%, which was not significantly different from that of Capnopen®. The doxorubicin and cisplatin tissue concentrations were greater with Capnopen®. Although there was no significant difference in the homogeneity of doxorubicin distribution between the two devices, the homogeneity of cisplatin distribution was significantly higher with Capnopen®. Conclusion The multi-nozzle PIPAC nebuliser did not fulfil expectations. Even though the surface spray patterns were broader with the multi-nozzle nebuliser, the tissue drug homogeneity and concentration were greater with Capnopen®. Graphical Abstract BackgroundMulti-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue drug delivery. Nonetheless, the advantages of such devices over one-nozzle nebulisers have not been demonstrated thus far. In this study, we compared the performance of multi- and one-nozzle nebulisers by conducting physical and ex vivo pharmacological experiments.MethodsThe one-nozzle nebuliser Capnopen® and the multi-nozzle nebuliser were the subjects of this study. In physical experiments, the aerosol droplet size was measured by laser diffraction spectroscopy. Spatial spray patterns were depicted on blotting paper. Pharmacological experiments were performed on the enhanced inverted bovine urinary bladder model, demonstrating real-time tissue drug delivery, aerosol sedimentation and homogeneity of doxorubicin and cisplatin tissue distribution.ResultsThe multi-nozzle nebuliser had a sixfold greater aerosolisation flow and a threefold greater angle of aerosolisation than Capnopen®. The aerosol particle size and distribution range were higher than that of Capnopen®. Spray patterns on blotting paper were more extensive with the multi-nozzle nebuliser. Real-time tissue drug delivery with the multi-nozzle nebuliser was over 100 ml within 1 min, and the aerosol sedimentation was 48.9% ± 21.2%, which was not significantly different from that of Capnopen®. The doxorubicin and cisplatin tissue concentrations were greater with Capnopen®. Although there was no significant difference in the homogeneity of doxorubicin distribution between the two devices, the homogeneity of cisplatin distribution was significantly higher with Capnopen®.ConclusionThe multi-nozzle PIPAC nebuliser did not fulfil expectations. Even though the surface spray patterns were broader with the multi-nozzle nebuliser, the tissue drug homogeneity and concentration were greater with Capnopen®. |
Author | Weinreich, Juergen Sautkin, Yaroslaw Reymond, Marc André |
Author_xml | – sequence: 1 givenname: Yaroslaw surname: Sautkin fullname: Sautkin, Yaroslaw email: Yaroslav_sautkin@gmx.de organization: National Center for Pleura and Peritoneum, University Hospital Tübingen, Department of General, Visceral and Transplant Surgery, University Hospital Tübingen – sequence: 2 givenname: Juergen surname: Weinreich fullname: Weinreich, Juergen organization: National Center for Pleura and Peritoneum, University Hospital Tübingen, Department of General, Visceral and Transplant Surgery, University Hospital Tübingen – sequence: 3 givenname: Marc André surname: Reymond fullname: Reymond, Marc André organization: National Center for Pleura and Peritoneum, University Hospital Tübingen, Department of General, Visceral and Transplant Surgery, University Hospital Tübingen |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39160309$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u3CAUhVGVqpmkfYEuKqRuuiHlAjawqkaj_kSJlCzaNcIYT4lsmII9UvL0tTtp2mSRFQu-e-6555ygo5iiR-gt0DOgVH4slIpaEMoEAQDJiHiBViA4I4yBOkIrqjklTGpxjE5KuaEzr6F6hY65hppyqlfoYo2HqR8Dienurvc4-mbqQ_EZt8kXHNOIw7DLae_xGEqZPG7ztMWt78Pe51vcTjnELb4-v15vXqOXne2Lf3P_nqIfXz5_33wjl1dfzzfrS-IEq0eiZ4fa8Y5rBm2nXON4oxuopXZOVZKyVnaWS8U62UmwlRK69UppK62SHXf8FH066O6mZvCt83HMtje7HAabb02ywTz-ieGn2aa9ARCVqiuYFT7cK-T0a_JlNEMozve9jT5NxczRCMVAKzGj75-gN2nKcb7PcACuFseL4Lv_LT14-Rv0DLAD4HIqJfvuAQFqljbNoU0zt2n-tGmW3fwwVHZLyj7_2_3M1G9yCKEu |
Cites_doi | 10.1245/s10434-013-3213-1 10.3762/bjnano.8.272 10.1245/s10434-019-07695-z 10.3390/cancers12010034 10.1080/02656736.2019.1704891 10.1007/s00464-012-2148-0 10.1515/pp-2018-0111 10.1515/pp-2016-0015 10.1515/pp-2019-0017 10.3390/cancers15041125 10.1515/pp-2017-0010 10.1002/pbc.29864 10.1101/2023.03.24.23287646 10.1080/10717544.2021.1937382 10.3390/cancers12030633 |
ContentType | Journal Article |
Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM |
DOI | 10.1007/s00464-024-11172-4 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1432-2218 |
EndPage | 5841 |
ExternalDocumentID | PMC11458651 39160309 10_1007_s00464_024_11172_4 |
Genre | Journal Article Comparative Study |
GrantInformation_xml | – fundername: Universitätsklinikum Tübingen (8868) – fundername: Capnopharm GmbH, Tübingen, Germany |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 203 28- 29Q 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAQQT AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABOCM ABPLI ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 WOW YLTOR Z45 Z7U Z7X Z82 Z83 Z87 Z88 Z8O Z8R Z8V Z8W Z91 Z92 ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY K9. 7X8 5PM |
ID | FETCH-LOGICAL-c426t-94329c3f3921df8cbc3b9b1679cc85702d7fa3782f7f71a5849de889a7a87f3c3 |
IEDL.DBID | U2A |
ISSN | 0930-2794 1432-2218 |
IngestDate | Thu Aug 21 18:35:44 EDT 2025 Mon Jul 21 10:58:37 EDT 2025 Sat Jul 26 00:37:44 EDT 2025 Mon Jul 21 06:02:27 EDT 2025 Tue Jul 01 03:24:20 EDT 2025 Fri Feb 21 02:40:19 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | Intraperitoneal drug delivery Peritoneal metastasis Pressurised intraperitoneal aerosol chemotherapy—PIPAC Nebuliser Peritoneum |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c426t-94329c3f3921df8cbc3b9b1679cc85702d7fa3782f7f71a5849de889a7a87f3c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://link.springer.com/10.1007/s00464-024-11172-4 |
PMID | 39160309 |
PQID | 3113885701 |
PQPubID | 31812 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11458651 proquest_miscellaneous_3094821984 proquest_journals_3113885701 pubmed_primary_39160309 crossref_primary_10_1007_s00464_024_11172_4 springer_journals_10_1007_s00464_024_11172_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-10-01 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: Germany |
PublicationSubtitle | And Other Interventional Techniques |
PublicationTitle | Surgical endoscopy |
PublicationTitleAbbrev | Surg Endosc |
PublicationTitleAlternate | Surg Endosc |
PublicationYear | 2024 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | Giger-Pabst, Bucur, Roger, Falkenstein, Tabchouri, Le Pape, Lerondel, Demtröder, Salamé, Ouaissi (CR4) 2019; 26 Sautkin, Solass, Weinreich, Königsrainer, Schenk, Thiel, Reymond (CR13) 2019; 4 Göhler, Große, Bellendorf, Falkenstein, Ouaissi, Zieren, Stintz, Giger-Pabst (CR14) 2017; 8 de Bree, Michelakis, Stamatiou, Romanos, Zoras (CR2) 2017; 2 Solass, Horvath, Struller, Königsrainer, Beckert, Königsrainer, Weinreich, Schenk (CR18) 2016; 1 Wagner, Adamus, Hempfling, Vahdad, Haap-Hoff, Heinrich, Vázquez, Jank, Denkert, Seitz (CR3) 2022; 69 Sautkin (CR9) 2024 Lee, Kim, Lee, Park, Mun, Paik, Oh, Park, Ryu, Lim, Song, Kim, Lee (CR15) 2020 CR17 Solaß, Hetzel, Nadiradze, Sagynaliev, Reymond (CR7) 2012; 26 Davigo, Passot, Vassal, Bost, Tavernier, Decullier, Bakrin, Alyami, Bonnet, Louzier, Paquet, Allaouchiche, Glehen, Kepenekian (CR6) 2020; 37 Park, Lee, Lee, Kim, Park, Ham, Mun, Paik, Lim, Seol, Yim, Shim, Kang, Chang, Lim, Song, Kim, Lee, Park, Lee, Kim (CR10) 2021; 28 Di Giorgio, Macrì, Ferracci, Robella, Visaloco, De Manzoni, Sammartino, Sommariva, Biacchi, Roviello, Pastorino, PiresMarafon, Rotolo, Casella, Vaira (CR19) 2023 CR12 CR11 Nadiradze, Horvath, Sautkin, Archid, Weinreich, Königsrainer, Reymond (CR1) 2019 Somashekhar, Ashwin, Rauthan, Rohit (CR8) 2019 Solass, Kerb, Mürdter, Giger-Pabst, Strumberg, Tempfer, Zieren, Schwab, Reymond (CR5) 2014; 21 Göhler, Oelschlägel, Ouaissi, Giger-Pabst (CR16) 2023 D Göhler (11172_CR14) 2017; 8 A Di Giorgio (11172_CR19) 2023 E de Bree (11172_CR2) 2017; 2 SJ Park (11172_CR10) 2021; 28 W Solass (11172_CR5) 2014; 21 11172_CR11 W Solass (11172_CR18) 2016; 1 11172_CR12 G Nadiradze (11172_CR1) 2019 I Sautkin (11172_CR9) 2024 D Göhler (11172_CR16) 2023 U Giger-Pabst (11172_CR4) 2019; 26 BR Wagner (11172_CR3) 2022; 69 11172_CR17 I Sautkin (11172_CR13) 2019; 4 HS Lee (11172_CR15) 2020 SP Somashekhar (11172_CR8) 2019 W Solaß (11172_CR7) 2012; 26 A Davigo (11172_CR6) 2020; 37 |
References_xml | – volume: 21 start-page: 553 year: 2014 end-page: 559 ident: CR5 article-title: Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy publication-title: Ann Surg Oncol doi: 10.1245/s10434-013-3213-1 – volume: 8 start-page: 2729 year: 2017 end-page: 2740 ident: CR14 article-title: Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): technical description, experimental validation and first proof of concept publication-title: Beilstein J Nanotechnol doi: 10.3762/bjnano.8.272 – volume: 26 start-page: 4445 year: 2019 end-page: 4451 ident: CR4 article-title: Comparison of tissue and blood concentrations of oxaliplatin administrated by different modalities of intraperitoneal chemotherapy publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07695-z – year: 2019 ident: CR1 article-title: Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC) publication-title: Cancers (Basel) doi: 10.3390/cancers12010034 – volume: 37 start-page: 144 year: 2020 end-page: 150 ident: CR6 article-title: PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model publication-title: Int J Hyperth doi: 10.1080/02656736.2019.1704891 – volume: 26 start-page: 1849 year: 2012 end-page: 1855 ident: CR7 article-title: Description of a novel approach for intraperitoneal drug delivery and the related device publication-title: Surg Endosc doi: 10.1007/s00464-012-2148-0 – year: 2019 ident: CR8 article-title: Pressurized IntraPeritoneal Aerosol chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer—study protocol for a randomized control trial publication-title: Pleura Peritoneum doi: 10.1515/pp-2018-0111 – ident: CR12 – ident: CR17 – ident: CR11 – volume: 1 start-page: 145 year: 2016 end-page: 158 ident: CR18 article-title: Functional vascular anatomy of the peritoneum in health and disease publication-title: Pleura Peritoneum doi: 10.1515/pp-2016-0015 – volume: 4 start-page: 20190017 year: 2019 ident: CR13 article-title: A real-time ex vivo model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models publication-title: Pleura Peritoneum doi: 10.1515/pp-2019-0017 – year: 2024 ident: CR9 publication-title: Quality-by-design optimization of intraperitoneal drug delivery with pressurized aerosols – year: 2023 ident: CR19 article-title: 10 Years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis publication-title: Cancers (Basel) doi: 10.3390/cancers15041125 – volume: 2 start-page: 47 year: 2017 end-page: 62 ident: CR2 article-title: Pharmacological principles of intraperitoneal and bidirectional chemotherapy publication-title: Pleura Peritoneum doi: 10.1515/pp-2017-0010 – volume: 69 start-page: e29864 year: 2022 ident: CR3 article-title: Increasing the efficiency of hyperthermic intraperitoneal chemotherapy (HIPEC) by combination with a photosensitive drug in pediatric rhabdomyosarcoma in an animal model publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.29864 – year: 2023 ident: CR16 article-title: Comparative analysis of nebulizers in clinical use for pressurized intraperitoneal aerosol chemotherapy (PIPAC) publication-title: medRxiv doi: 10.1101/2023.03.24.23287646 – volume: 28 start-page: 1179 year: 2021 end-page: 1187 ident: CR10 article-title: Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum publication-title: Drug Deliv doi: 10.1080/10717544.2021.1937382 – year: 2020 ident: CR15 article-title: Evaluation of a novel prototype for pressurized intraperitoneal aerosol chemotherapy publication-title: Cancers (Basel) doi: 10.3390/cancers12030633 – volume: 26 start-page: 4445 year: 2019 ident: 11172_CR4 publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07695-z – volume: 37 start-page: 144 year: 2020 ident: 11172_CR6 publication-title: Int J Hyperth doi: 10.1080/02656736.2019.1704891 – volume: 1 start-page: 145 year: 2016 ident: 11172_CR18 publication-title: Pleura Peritoneum doi: 10.1515/pp-2016-0015 – ident: 11172_CR12 – ident: 11172_CR17 – ident: 11172_CR11 – volume: 26 start-page: 1849 year: 2012 ident: 11172_CR7 publication-title: Surg Endosc doi: 10.1007/s00464-012-2148-0 – year: 2019 ident: 11172_CR1 publication-title: Cancers (Basel) doi: 10.3390/cancers12010034 – year: 2023 ident: 11172_CR19 publication-title: Cancers (Basel) doi: 10.3390/cancers15041125 – volume: 69 start-page: e29864 year: 2022 ident: 11172_CR3 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.29864 – volume: 28 start-page: 1179 year: 2021 ident: 11172_CR10 publication-title: Drug Deliv doi: 10.1080/10717544.2021.1937382 – year: 2023 ident: 11172_CR16 publication-title: medRxiv doi: 10.1101/2023.03.24.23287646 – volume: 21 start-page: 553 year: 2014 ident: 11172_CR5 publication-title: Ann Surg Oncol doi: 10.1245/s10434-013-3213-1 – volume: 8 start-page: 2729 year: 2017 ident: 11172_CR14 publication-title: Beilstein J Nanotechnol doi: 10.3762/bjnano.8.272 – volume-title: Quality-by-design optimization of intraperitoneal drug delivery with pressurized aerosols year: 2024 ident: 11172_CR9 – year: 2020 ident: 11172_CR15 publication-title: Cancers (Basel) doi: 10.3390/cancers12030633 – volume: 4 start-page: 20190017 year: 2019 ident: 11172_CR13 publication-title: Pleura Peritoneum doi: 10.1515/pp-2019-0017 – year: 2019 ident: 11172_CR8 publication-title: Pleura Peritoneum doi: 10.1515/pp-2018-0111 – volume: 2 start-page: 47 year: 2017 ident: 11172_CR2 publication-title: Pleura Peritoneum doi: 10.1515/pp-2017-0010 |
SSID | ssj0004915 |
Score | 2.4532099 |
Snippet | Background
Multi-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity... Multi-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity of tissue... BackgroundMulti-nozzle nebulisers for pressurised intraperitoneal aerosol chemotherapy (PIPAC) are implemented in clinical practice to improve the homogeneity... |
SourceID | pubmedcentral proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 5832 |
SubjectTerms | Abdominal Surgery Administration, Inhalation Aerosols Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Bladder Cattle Chemotherapy Cisplatin - administration & dosage Cisplatin - pharmacokinetics Cytotoxicity Doxorubicin - administration & dosage Doxorubicin - pharmacokinetics Drug delivery systems Drug Delivery Systems - instrumentation Drugs Endoscopy Equipment Design Experiments Gastroenterology Gynecology Hepatology Lasers Medicine Medicine & Public Health Nebulizers and Vaporizers Nozzles Particle Size Proctology Spectrum analysis Surgery Tissue Distribution Urinary Bladder |
Title | A multi-nozzle nebuliser does not improve tissue drug delivery during PIPAC |
URI | https://link.springer.com/article/10.1007/s00464-024-11172-4 https://www.ncbi.nlm.nih.gov/pubmed/39160309 https://www.proquest.com/docview/3113885701 https://www.proquest.com/docview/3094821984 https://pubmed.ncbi.nlm.nih.gov/PMC11458651 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV05T8MwFH6CVkIsiJtyVEZiA0skdhJnTCtKAYEYqARTlMOGSlWC2nSgv55n50DlGJgy2LKTd_h9L-8wwJkGDS56FtTjEaNcoKb7Ul6i4kk0TxFaDKULnO8f3OGI3z47z1VR2KzOdq9DkuakbordTBSOok2hqJ-eTfkqtB3tu6MUj-zgqxrSL-8t8NkltVHcqlKZ39dYNkc_MObPVMlv8VJjhgabsFHhRxKUDN-CFZltw9p9FSHfgbuAmBxBmuWLxUSSTMb6ynM5JWkuZyTLCzI2_xEkKQzNSTqdv5JUTnSCxgcpyxbJ481j0N-F0eDqqT-k1YUJNEFDW1CfM9tPmELMY6VKJHHCYj_WgZYk0Y3s7dRTEUNMoDzlWRFiDz-VQviRFwlPsYTtQSvLM3kAJFIOAgFmKZzKHSeNuWvz1LKY5arY8kQHzmu6he9lX4yw6YBsqBwilUND5ZB34LgmbVjpyCxkuJrQr2V14LQZRunWIYsok_kc56D3KfBQFbjEfsmJZjtdMqwDRB0QSzxqJujO2csj2fjNdNBGJ9ARroMbX9Ts_Hqvvz_j8H_Tj2DdNqKmU_-OoVVM5_IEIUwRd6EdDHq9B_28frm76sJq3-13jRx_Akd06dw |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT8MwDLZgSMAF8WYwIEjcINLapG16nCamjT3EgUm7VX0kMGlq0dYd2K_HSbtN43HgXCtJ_ajt2v4CcK-DBhczC-rxkFEu0NJ9KetoeBLdU4geQ-kB5_7AbQ_588gZlTA5ehbmW_3egH26nKInoWiVnk35NuxwzJR1-17Tba5nIP3itgKf1amNSlYOyPy-xqYT-hFZ_myQ_FYlNc6ndQgHZdRIGoWYj2BLpsew2y_r4ifQbRDTGUjTbLGYSJLKSF90LqckyeSMpFlOxubvgSS54TRJpvM3ksiJbsv4JMWwInnpvDSapzBsPb0227S8JoHG6F5z6nNm-zFTGOlYiRJxFLPIj3R5JY41fL2deCpkGAkoT3lWiBGHn0gh_NALhadYzM6gkmapvAASKgfdP7MUknLHSSLu2jyxLGa5KrI8UYWHJd-CjwINI1jhHhsuB8jlwHA54FWoLVkblJYxCxiuJvSxrCrcrR6jTutCRZjKbI40mHMK_JQKXOK8kMRqOz0orMtCVRAbMloRaLzszSfp-N3gZmPq5wjXwY0fl-Jcn-vv17j8H_kt7LVf-72g1xl0r2DfNmqnm_9qUMmnc3mNQUwe3Rjt_QK7yuTB |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JTsMwEB2xSIgLYqesRuIGFiR2EudYFSp29QAStyiJbaiEHNSmB_r1jJ00UJYD54xsZ5bMm8xigCMLGkKMLGjEU0a5QEuPlTpDw1PonlL0GNo2ON_dh5eP_PopePrSxe-q3ScpyaqnwU5pMuXpm9SnTeOby8hR9C8UbTXyKZ-FeYxUXKK2E3Y-OyPj6g6DmJ1RH1Wvbpv5fY1p1_QDb_4sm_yWO3UuqbsMSzWWJO1K-Cswo8wqLNzV2fI1uGkTVy9ITTEevypiVGavP1cDIgs1JKYoSd_9U1CkdPwncjB6JlK92mKNd1K1MJLeVa_dWYfH7sVD55LWlyfQHJ1uSWPO_DhnGvGPJ7XIs5xlcWaTLnluh9r7MtIpQ3ygIx15KeKQWCoh4jRKRaRZzjZgzhRGbQFJdYCggHkaSXkQyIyHPpeex7xQZ14kWnA84VvyVs3ISJppyI7LCXI5cVxOeAt2J6xNansZJgxXE_ZYXgsOm8eo6TZ9kRpVjJAGI1GBH1iBS2xWkmi2s-3DNlnUAjElo4bATtGefmL6L26aNgaEgQgD3PhkIs7Pc_39Gtv_Iz-Ahd55N7m9ur_ZgUXfaZ2tCNyFuXIwUnuIbMps3ynvB74p7Qg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+multi-nozzle+nebuliser+does+not+improve+tissue+drug+delivery+during+PIPAC&rft.jtitle=Surgical+endoscopy&rft.au=Sautkin%2C+Yaroslaw&rft.au=Weinreich%2C+Juergen&rft.au=Reymond%2C+Marc+Andr%C3%A9&rft.date=2024-10-01&rft.pub=Springer+US&rft.issn=0930-2794&rft.eissn=1432-2218&rft.volume=38&rft.issue=10&rft.spage=5832&rft.epage=5841&rft_id=info:doi/10.1007%2Fs00464-024-11172-4&rft.externalDocID=10_1007_s00464_024_11172_4 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0930-2794&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0930-2794&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0930-2794&client=summon |